Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
Goh SY, Kosiborod MN, Lam CSP, Cavender MA, Kohsaka S, Norhammar A, Birkeland KI, Holl RW, Mauricio D, Tangri N, Shaw JE, Thuresson M, Fenici P, Kim DJ; CVD-REAL Investigators and Study Group. Goh SY, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Aug;25(8):2402-2409. doi: 10.1111/dom.15092. Epub 2023 May 8. Diabetes Obes Metab. 2023. PMID: 37055714 No abstract available.
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Among authors: holl rw. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: holl rw. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: holl rw. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Surfing the waves of the COVID-19 pandemic with diabetes mellitus: Analysis of changes in the diabetes therapy, metabolism and physical activity of 92 992 people living with type 1 or type 2 diabetes from the German DPV registry.
Hartmann B, Tittel SR, Gillesen A, Klarl B, Kopp F, Meyhöfer S, Naudorf M, Schilling M, Wosch FJ, Holl RW; DPV Initiative. Hartmann B, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Sep;25(9):2774-2779. doi: 10.1111/dom.15149. Epub 2023 May 31. Diabetes Obes Metab. 2023. PMID: 37254679 No abstract available.
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Brandts J, Tittel SR, Bramlage P, Danne T, Brix JM, Zimny S, Heyer CHJ, Holl RW, Müller-Wieland D. Brandts J, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Dec;25(12):3700-3708. doi: 10.1111/dom.15264. Epub 2023 Sep 11. Diabetes Obes Metab. 2023. PMID: 37694759
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry.
Kress S, Bramlage P, Holl RW, Möller CD, Mühldorfer S, Reindel J, Seufert J, Landgraf R, Merker L, Meyhöfer SM, Danne T, Fasching P, Mertens PR, Wanner C, Lanzinger S. Kress S, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Mar;25(3):776-784. doi: 10.1111/dom.14925. Epub 2022 Dec 20. Diabetes Obes Metab. 2023. PMID: 36444743
Who benefits most from outpatient lifestyle intervention? An IMI-SOPHIA study on pediatric individuals living with overweight and obesity.
Prinz N, Pomares-Millan H, Dannemann A, Giordano GN, Joisten C, Körner A, Weghuber D, Weihrauch-Blüher S, Wiegand S, Holl RW, Lanzinger S; APV initiative and the Stratification of Obesity Phenotypes to Optimize Future Therapy (SOPHIA) consortium. Prinz N, et al. Among authors: holl rw. Obesity (Silver Spring). 2023 Sep;31(9):2375-2385. doi: 10.1002/oby.23844. Epub 2023 Aug 6. Obesity (Silver Spring). 2023. PMID: 37545199
Response to "Commentary on factors associated with diabetic foot ulcers and lower limb amputations in type 1 and type 2 diabetes supported by real-world data from the German/Austrian DPV registry".
Eckert AJ, Zimny S, Altmeier M, Dugic A, Gillessen A, Bozkurt L, Götz G, Karges W, Wosch FJ, Kress S, Holl RW; DPV‐Wiss‐Initiative. Eckert AJ, et al. Among authors: holl rw. J Diabetes. 2024 Dec;16(12):e70036. doi: 10.1111/1753-0407.70036. J Diabetes. 2024. PMID: 39624915 Free PMC article. No abstract available.
Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries.
Zimmermann AT, Lanzinger S, Kummernes SJ, Lund-Blix NA, Holl RW, Fröhlich-Reiterer E, Maahs DM, Ebekozien O, Rompicherla S, Warner JT, Pons Perez S, Robinson H, Craig ME, Johnson S, Akesson K, Thorén A, Eeg-Olofsson K, Ranjan AG, Madsen M, Witsch M, Bratke H, Alonso GT, Sumnik Z, Neuman V, Cinek O, Skrivarhaug T, Svensson J. Zimmermann AT, et al. Among authors: holl rw. Lancet Diabetes Endocrinol. 2024 Nov 28:S2213-8587(24)00279-1. doi: 10.1016/S2213-8587(24)00279-1. Online ahead of print. Lancet Diabetes Endocrinol. 2024. PMID: 39622257
561 results